In separate clinical trials, adults taking the highest tablet dose lost about 14% of their body weight on average over one year; those on the standard 2.4mg weekly injection lost about 15% over 68 weeks. The pill is approved for weight management in adults with a body mass index of 30 or above, or 27 or above with at least one weight-related health condition. It is prescribed alongside dietary changes and increased physical activity, with the dose increased gradually under medical supervision.
The tablet is not subsidised under the Pharmaceutical Benefits Scheme, so patients pay the full pharmacy price. Novo Nordisk recommends a monthly cost of $260 for the starting dose, rising to $395 for the highest dose. Bronger said prices and availability would vary between pharmacies over the next week.
Sydney GP Dr Anjali Didi said regular appointments help manage side effects and review dosage. Nausea, vomiting and diarrhoea were among the most commonly reported side effects in the tablet trial; pancreatitis is a more serious risk.
